Ipamorelin vs GHRP-2 vs GHRP-6: Growth Hormone Secretagogue Comparison

Growth hormone secretagogues (GHS) represent one of the most actively researched peptide classes in endocrinology and metabolic science. By stimulating endogenous GH release from the anterior pituitary — rather than replacing GH directly — these compounds allow researchers to study the natural pulsatile GH axis in preclinical and clinical models. Three peptides dominate this research space: ipamorelin, GHRP-2 (pralmorelin), and GHRP-6. They share a receptor target but differ meaningfully in selectivity, side-effect profiles, and what the published evidence shows.

Background: The GH Secretagogue Receptor (GHSR-1a)

All three peptides act as agonists at the growth hormone secretagogue receptor 1a (GHSR-1a) — a G protein-coupled receptor (GPCR) that is the endogenous receptor for ghrelin. GHSR-1a is expressed at highest density in the anterior pituitary, hypothalamus (particularly the arcuate and ventromedial nuclei), and vagal afferents in the gastrointestinal tract. When activated, it triggers the Gq/PLC signaling cascade, leading to IP3-mediated calcium release and downstream activation of the GH secretory apparatus in somatotroph cells.

The critical distinction between the three peptides is not their primary receptor — all are GHSR-1a agonists — but how selectively they hit this target, what their relative potency is at GHSR-1a versus other receptors, and what downstream hormonal effects they trigger beyond GH. Understanding these differences is essential for selecting the right tool for a given research question.

Ipamorelin: The Selective GHS

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) was developed by Novo Nordisk in the late 1990s as a highly selective GHSR-1a agonist. Its development rationale was specifically to isolate GH stimulation while minimizing the off-target hormonal effects that had limited earlier GHRP compounds. The defining characteristic of ipamorelin is its selectivity: at equimolar doses that produce maximal GH release, it does not significantly stimulate cortisol, ACTH, or prolactin secretion.

The mechanism behind this selectivity is structural. Ipamorelin's D-2-naphthylalanine residue at position 3 — absent in GHRP-2 and GHRP-6 — appears to confer a binding geometry at GHSR-1a that is tightly receptor-selective. Studies comparing ipamorelin to GHRP-2 in rat pituitary cell cultures found that ipamorelin failed to activate ACTH pathways at concentrations that produced maximal GH stimulation, while GHRP-2 activated both.

• Primary receptor: GHSR-1a (selective — minimal off-target activity)
• Molecular weight: 711.9 g/mol
• GH stimulation: Potent, dose-dependent, equivalent to GHRP-2 at equimolar doses in most models
• Cortisol/ACTH effect: Minimal at effective GH-stimulating doses — the key differentiator
• Prolactin effect: None significant
• Hunger stimulation: Modest compared to GHRP-6; not a primary effect
• Half-life: ~2 hours (subcutaneous); short enough for discrete pulse research designs

In published rodent studies, ipamorelin produces dose-dependent increases in plasma GH with an ED50 of approximately 80-100 nmol/kg subcutaneously. It has been shown to increase IGF-1 levels with chronic administration in rat models, confirming that the GH pulses it stimulates are biologically productive. In a 2-year rat growth study, ipamorelin administration produced linear growth rates comparable to growth hormone itself without adverse effects on pituitary morphology.

GHRP-2 (Pralmorelin): High Potency, Moderate Off-Target Effects

GHRP-2 (D-Ala-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2) is one of the most potent synthetic GHSR-1a agonists in the research catalog. It was among the first synthetic GHRPs to be evaluated in human clinical pharmacology studies, and its pharmacological profile is the closest to GHRP-6 of the three compounds — with notably higher potency on a molar basis.

GHRP-2's key characteristic is its potency: it is approximately 2-4x more potent than ipamorelin and GHRP-6 for GH stimulation in most in vivo models. However, this potency comes with a trade-off — GHRP-2 significantly increases cortisol and ACTH in human subjects at doses producing maximal GH release. These effects are mediated through GHSR-1a activity at corticotroph cells and through CRH-dependent pathways in the hypothalamus.

• Primary receptor: GHSR-1a (potent, less selective than ipamorelin)
• Molecular weight: 817.9 g/mol
• GH stimulation: Highest absolute GH peak of the three compounds at equivalent molar doses
• Cortisol/ACTH effect: Significant — documented 2-3x increases in plasma cortisol in human studies
• Prolactin effect: Modest increase
• Hunger stimulation: Moderate (weaker than GHRP-6)
• Half-life: ~1.5-2 hours

Despite its off-target hormonal effects, GHRP-2 is valuable when maximal acute GH secretion is the study endpoint. It has also been used clinically in GH stimulation testing (the GHRP-2 test for GH deficiency diagnosis) in countries where it is approved for diagnostic use.

GHRP-6: The Ghrelin Mimetic with Appetite Effects

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is historically one of the first synthetic GHRPs characterized and was instrumental in identifying what would later become the ghrelin receptor. Its structure most closely resembles the active core of native ghrelin among the three compounds, reflected in its pharmacological profile — it is a broad-spectrum GHSR agonist that recapitulates much of ghrelin's hormonal and metabolic effects beyond GH release.

The defining feature distinguishing GHRP-6 from ipamorelin and GHRP-2 is its potent appetite and hunger stimulation. GHRP-6 activates GHSR-1a in hypothalamic circuits that regulate energy homeostasis — particularly in the arcuate nucleus, where ghrelin signals orexigenic peptide neurons. In human studies, GHRP-6 produces a pronounced subjective hunger response within 30-90 minutes that is significantly stronger than ipamorelin or GHRP-2 at equi-effective GH-stimulating doses.

• Primary receptor: GHSR-1a (broadest off-target activity profile of the three)
• Molecular weight: 873.0 g/mol
• GH stimulation: Potent, approximately equivalent to ipamorelin on molar basis; less potent than GHRP-2
• Cortisol/ACTH effect: Moderate increase, intermediate between ipamorelin and GHRP-2
• Prolactin effect: Moderate increase
• Hunger stimulation: Pronounced — the strongest hunger side effect of the three; mediated through NPY/AgRP hypothalamic circuits
• Half-life: ~1.5-2 hours

Head-to-Head: Key Differentiators

• Maximum GH peak needed → GHRP-2 (highest absolute GH response on molar basis)
• Clean, isolated GH signal without cortisol confound → Ipamorelin (best selectivity)
• Study requires ghrelin-like full receptor agonism including appetite effects → GHRP-6
• Long-term GH axis stimulation without HPA axis activation → Ipamorelin (2-year rat data, no cortisol elevation)
• GH stimulation test / diagnostic protocol → GHRP-2 (established in clinical GH testing)
• Combine with GHRH or CJC-1295 for amplified GH response → All three work; ipamorelin most commonly used due to selectivity

Combination Protocols: GHS + GHRH

An important feature of GHSR-1a agonists is their synergistic interaction with growth hormone-releasing hormone (GHRH). When GHRH and a GHSR-1a agonist are administered simultaneously, the resulting GH pulse is significantly larger than either compound produces alone — often 5-10x the individual response. This synergy is exploited in body composition and metabolic research requiring robust GH-IGF-1 axis activation.

In combination protocols, ipamorelin is the most commonly used GHS component because its selectivity means the combined stimulus remains clean in terms of cortisol and ACTH — allowing researchers to attribute any glucocorticoid effects to elevated GH/IGF-1 signaling rather than direct ACTH stimulation.

Published Study Data

Ipamorelin

The clearest ipamorelin data comes from the Novo Nordisk development program (late 1990s). Johansen et al. (1999) demonstrated dose-dependent GH secretion in rats and dogs, with no significant increase in ACTH or cortisol at doses up to 500 nmol/kg. Chronic 12-week administration at 125 nmol/kg/day produced sustained increases in IGF-1, body weight, and bone mineral density without pituitary downregulation or tachyphylaxis — a chronic tolerance profile that distinguishes ipamorelin from earlier GHRPs.

GHRP-2

GHRP-2 has the richest clinical dataset of the three. Human pharmacology studies report peak GH responses of 50-70 ng/mL following 1 mcg/kg IV or 2-4 mcg/kg subcutaneous dosing. Arvat et al. (1997) showed that GHRP-2 at 1 mcg/kg IV produced a 2.3-fold increase in plasma cortisol peaking at 60 minutes — a receptor-mediated effect relevant to researchers designing clean GH studies.

GHRP-6

Bowers et al. characterized GHRP-6's GH-stimulating properties and identified the hunger effect as a consistent and reproducible finding across subjects. In healthy volunteers, 1 mcg/kg IV GHRP-6 produces peak GH of 30-50 ng/mL with simultaneous increases in appetite ratings within 30 minutes. The orexigenic effect persists even when GH secretion is blocked by somatostatin infusion, confirming the hunger stimulus is a direct hypothalamic GHSR-1a effect, not secondary to GH elevation.

Dosing Protocols in Preclinical Research

• Ipamorelin in rats/mice: 125-500 nmol/kg subcutaneous; once or twice daily for chronic protocols; some studies use minipump infusion at 25-50 nmol/kg/hr
• GHRP-2 in rats/mice: 100-300 nmol/kg subcutaneous for acute GH stimulation
• GHRP-6 in rats/mice: 100-300 nmol/kg subcutaneous for acute GH; 1-10 mg/kg IP for appetite/food intake studies
• Combination (GHS + GHRH/CJC-1295): GHS at 50-100 nmol/kg paired with GHRH analog for supra-additive GH responses
• Pulsatile vs. continuous: pulsatile dosing (twice daily) maintains GH axis sensitivity better than continuous infusion
• Vehicle: sterile saline for acute studies; bacteriostatic water for multi-dose protocols

Receptor Desensitization

GHSR-1a undergoes homologous desensitization — repeated agonist stimulation reduces receptor surface expression and G-protein coupling efficiency. Ipamorelin shows the slowest desensitization: approximately 70-80% of acute GH response retained after 12 weeks of twice-daily administration. GHRP-6 shows faster tachyphylaxis in continuous infusion models. For chronic GH axis studies, use pulsatile dosing with at least 6-8 hour inter-dose intervals to allow receptor recycling.

Reconstitution and Handling

• Allow vials to reach room temperature before opening to prevent condensation moisture entry
• Add sterile water or bacteriostatic water slowly to the vial wall (not directly onto the powder)
• Gently swirl or invert to dissolve; avoid vortexing
• Typical working concentrations: 1-2 mg/mL for injection protocols
• Reconstituted solutions at 4°C: stable 3-4 weeks in bacteriostatic water, 5-7 days in sterile water
• Lyophilized: stable at -20°C for 24+ months in sealed vials
• Aliquot reconstituted solutions into single-use volumes before freezing to avoid freeze-thaw cycling

Choosing the Right Compound

• GH secretion isolated from HPA axis effects → Ipamorelin. Cleanest pharmacological probe for the GH axis.
• Maximal acute GH release, cortisol confounders acceptable → GHRP-2. Highest potency for peak GH endpoint studies.
• Ghrelin receptor biology, appetite circuits, orexigenic signaling → GHRP-6. Broader ghrelin-mimetic profile for energy homeostasis research.
• Clean GHRH combination protocol → Ipamorelin + GHRH is the standard in published literature.
• Pituitary reserve or GH deficiency diagnosis models → GHRP-2 has the most clinical validation as a provocative test compound.

Regulatory Note

Ipamorelin, GHRP-2, and GHRP-6 are sold as research chemicals for laboratory use only. None are FDA-approved for therapeutic use. The effects described in this article are drawn from published preclinical and clinical pharmacology research conducted in controlled settings. This content is for scientific informational purposes only.